

1 ***CFH* loss in human RPE cells leads to inflammation and complement system**
2 **dysregulation *via* the NF- κ B pathway**

3

4 **Running title:** *CFH* loss leads to NF- κ B mediated inflammation

5

6 Angela Armento*¹, Tiziana L Schmidt*¹, Inga Sonntag*, David Merle*, Mohamed Ali
7 Jarboui*, Ellen Kilger*, Simon J. Clark*^{†‡}; Marius Ueffing*[†]

8

9 * Institute for Ophthalmic Research, Department for Ophthalmology, Eberhard Karls
10 University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany

11 † University Eye Clinic, Department for Ophthalmology, Eberhard Karls University of
12 Tübingen, Tübingen, Baden-Württemberg, 72076, Germany

13 ‡ Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and
14 Health, University of Manchester, Manchester, M13 9PT, UK

15

16 corresponding authors:

17 Angela Armento, PhD

18 Institute for Ophthalmic Research, Department for Ophthalmology, Eberhard Karls University
19 of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany

20 angela.armento@uni-tuebingen.de

21 Phone: +49 7071 29 84953

22

23 Marius Ueffing, PhD.

24 Institute for Ophthalmic Research, Department for Ophthalmology, Eberhard Karls University
25 of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany

26 marius.ueffing@uni-tuebingen.de

27

28 ¹ These authors contributed equally

29

30 Angela Armento is supported by the fortune-Programm (project number 2640-0-0). This work
31 was supported by donations from Jutta Emilie Paula Henny Granier and the Kerstan Foundation
32 to Marius Ueffing and the Helmut Ecker Foundation to Simon J Clark.

33 **Abstract**

34 Age-related macular degeneration (AMD), the leading cause of vision loss in the elderly, is a
35 degenerative disease of the macula, where retinal pigment epithelium (RPE) cells are damaged
36 in the early stages of the disease and chronic inflammatory processes may be involved. Besides
37 ageing and lifestyle factors as drivers of AMD, a strong genetic association to AMD is found
38 in genes of the complement system, with a single polymorphism in the complement factor H
39 gene (*CFH*), accounting for the majority of AMD risk. However, the exact mechanism by which
40 *CFH* dysregulation confers such a great risk for AMD and its role in RPE cells homeostasis is
41 unclear. To explore the role of endogenous *CFH* locally in RPE cells, we silenced *CFH* in
42 human hTERT-RPE1 cells. We demonstrate that endogenously expressed *CFH* in RPE cells
43 modulates inflammatory cytokine production and complement regulation, independent of
44 external complement sources or stressors. We show that loss of the factor H protein (FH) results
45 in increased levels of inflammatory mediators (*e.g.* IL-6, IL-8, GM-CSF) and altered levels of
46 complement proteins (*e.g.* C3, *CFB* upregulation and C5 downregulation) that are known to
47 play a role in AMD. Moreover, we identified the NF- κ B pathway as the major pathway involved
48 in the regulation of these inflammatory and complement factors. Our findings suggest that in
49 RPE cells, FH and the NF- κ B pathway work in synergy to maintain inflammatory and
50 complement balance and in case either one of them is dysregulated, the RPE microenvironment
51 changes towards a pro-inflammatory AMD-like phenotype.

52

53

54 **Introduction**

55 The specific anatomic structure of the human eye permits a tightly regulated local immune
56 response to be sufficient in protecting the retina from external pathogens and to maintain its
57 visual function (1). In immune privileged organs like the eye an excessive immune response,
58 and the subsequent recruitment of circulating immune cells, may lead to tissue damage and
59 affect the function of such a highly specified organ. Ocular immune privilege is mainly ensured
60 by the physical barrier formed by the retinal pigment epithelium (RPE) cell monolayer sitting
61 on an extracellular matrix (ECM), called Bruch's membrane (BrM), which separates the
62 neurosensory retina from the choroid and choriocapillaris (2). The main advantage of an intact
63 RPE/BrM interface is that it provides an effective barrier for the selectivity of molecular
64 diffusion, especially with regard to a possible systemic inflammatory insult (3). Considering
65 that the composition of BrM relies on the deposition of ECM components from both the
66 endothelium cells of the choriocapillaris and the RPE cells, any disruption to RPE cell
67 homeostasis is deleterious for effective barrier maintenance. Moreover, RPE cells exert several
68 other functions needed for retinal health. RPE cells are not only responsible for the phagocytosis
69 and recycling of photoreceptor outer segments (POS), but they also possess antioxidant activity
70 and actively take up nutrients from, and release discard material into, the BrM (4). Although
71 increased signs of inflammation are observed in several retinal degenerative diseases (5), the
72 combination of RPE cell dysfunction, barrier breakdown and subtle, chronic, inflammation is
73 characteristic for the disease age-related macular degeneration (AMD) (6).

74 AMD is a progressive degenerative disease of the retina, which leads to patients losing
75 their central vision and, in later stages, suffering blindness (7). AMD affects foremost the
76 elderly population and it is estimated that with increasing life expectancy around 300 million
77 people will be affected by 2040 (8). A hallmark of the disease is the presence of deposits, called
78 drusen, within BrM underneath the RPE cells, which not only impair RPE function but also
79 greatly alter the properties of BrM (9). The events that lead to these changes are not yet fully
80 understood, however it is known that AMD is caused by a combination of ageing, genetic
81 predisposition and lifestyle (10-12). The majority of genetic risk lies in the genes of the
82 alternative pathway of the complement system (13), which is an important part of the innate
83 immune system. The canonical role of the complement system is to recognize and mediate the
84 removal of pathogens, debris and dead cells *via* the activation of the complement proteolytic
85 cascade (14). Clearly, tight regulation of complement activation is required to prevent
86 inflammation-induced tissue damage, especially in an immune privileged organ like the eye
87 (15). At the site of complement activation the release of the cleaved complement factors C3a

88 and C5a, called anaphylatoxins, leads to the recruitment and activation of circulating immune
89 cells such as macrophages and leucocytes (16). Additionally, C3a and C5a activate resident
90 immune cells, like microglia and Muller cells, generating a chronic inflammatory environment,
91 which is observed in AMD (17, 18). Complement dysregulation is not only linked to AMD *via*
92 genetic association. Several complement activation products have also been detected in drusen,
93 as well as in the eyes and in the blood of AMD patients (9, 19, 20). One of the most common
94 genetic risks, accounting for 50% of attributable risk for AMD, corresponds to a polymorphism
95 in the complement factor H (*CFH*) gene that consists of a Tyr to His amino acid substitution at
96 position 402 in the pre-processed factor H protein (FH: position 384 in the mature FH protein)
97 (21, 22). The Y402H polymorphism is also present in the alternative splicing product of the
98 *CFH* gene, the protein called factor H-like protein 1 (FHL-1), which is around a third of the
99 size of FH and found to predominate in BrM (23). FH and FHL-1 are negative regulators of the
100 alternative pathway of the complement system and promote the degradation of C3b, a
101 breakdown product of C3 and the central component of the complement activation
102 amplification loop (24). The AMD high-risk genetic variant *CFH* 402H is believed to be
103 involved in AMD pathogenesis in different ways. Indeed, besides the fact that the FH/FHL-1
104 402H variant has been associated with increased complement activation (25), the same variant
105 also shows reduced binding affinity to ECM components (*e.g.* heparan sulphate) (26), oxidized
106 lipids (*e.g.* malondialdehyde MDA) (27) and inflammatory mediators (*e.g.* C-reactive protein
107 CRP) (28, 29). Most importantly, the function of the FH/FHL-1 proteins may differ depending
108 on their source and location (24, 30). Indeed, in this regard, the endogenous impact of *CFH*
109 proteins in RPE cells has rarely been investigated. In our recent study, we unraveled a non-
110 canonical function of endogenous FH, as the predominant splice form found in RPE cells. By
111 silencing *CFH* in hTERT-RPE1 cells, we showed that FH loss in RPE cells not only modulates
112 the extracellular microenvironment *via* its regulation of C3 levels, but also has an intracellular
113 impact on the antioxidant functions and metabolic homeostasis of RPE cells (31). In the current
114 study, the same model was employed to investigate the endogenous role of FH in the
115 inflammatory response of RPE cells, since RPE cells actively contribute to the maintenance of
116 the immune privileged status of the eye, and not only *via* their barrier function. In particular,
117 we focused on the interactions between FH, inflammation and the nuclear factor kappa-light-
118 chain-enhancer of activated B cells (NF- κ B) pathway in RPE cells. The NF- κ B pathway is a
119 known key regulator of inflammation and upon canonical regulation of this pathway, the p65
120 subunit (RelA) of the NF- κ B complex is phosphorylated and translocates to the nucleus, where
121 it promotes the transcription of several NF- κ B target genes, including inflammatory cytokines,

122 chemokines and also genes involved oxidative stress response (32). Activation of the NF- κ B
123 pathway has been associated with several neurodegenerative diseases, including Alzheimer's
124 and Parkinson's disease (33), but also in retinal degenerative diseases, such as diabetic
125 retinopathy (34).

126 Here, we show that RPE cells are immunocompetent with respect to their ability to
127 express and regulate immune-modulatory genes including cytokines and chemokines. FH loss
128 results in an increase of inflammatory cytokines and chemokines in an NF- κ B dependent
129 fashion. Moreover, we discovered that FH loss strongly alters the regulation of other
130 complement genes, again in an NF- κ B dependent way, thereby creating a dysfunction in
131 complement pathway regulation. As such, the NF- κ B pathway emerged as a major signaling
132 pathway controlling immune competence and response in RPE cells.

133

134 **Material and Methods**

135 **Cell culture and experimental settings**

136 The human RPE cell line hTERT-RPE1 was obtained from the American Type Culture
137 Collection (ATCC). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM;
138 Gibco, Germany) containing 10% fetal calf serum (FCS; Gibco, Germany), penicillin (100
139 U/ml), streptomycin (100 µg/ml) in a humidified atmosphere containing 5% CO₂. Cells were
140 seeded in complete growth medium without phenol red in 12-well plates and allowed to attach
141 overnight. Gene silencing was performed with Viromer Blue reagent according to the
142 manufacturer's instructions (Lipocalyx, Germany). Culture medium was substituted with fresh
143 medium and siRNA mixture was added dropwise. We employed a mix of three different double
144 strand hairpin interference RNAs specific for either *CFH* or *RELA* and a negative control (Neg),
145 recommended by the provider (IDT technologies, Belgium). In experiments where double
146 silencing was required (siCFH + siRELA), an additional amount of siNeg siRNA was added in
147 the single silencing samples (siNeg, siRELA and siCFH) to keep equal concentrations. Cells
148 were then maintained in serum free medium for the indicated time and where indicated, medium
149 was supplemented with FH (1 µg/ml), C3 (0.1 µg/ml) or C3b (0.1 µg/ml) (CompTech, Texas,
150 USA) for 48 or 144 hours (h).

151

152 **RNA extraction, cDNA synthesis and quantitative RT-PCR**

153 At the indicated time points, total RNA was extracted with PureZOL reagent, according to the
154 manufacturer's instructions (Bio-Rad Laboratories, USA) and cDNA was synthesized *via*
155 reverse-transcription of 1 µg of RNA using M-MLV Reverse Transcriptase (Promega
156 (Wisconsin, USA). cDNA was used to analyse differences in gene expression by qRT-PCR
157 employing iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories, USA) along with
158 gene specific forward and reverse primers (10 µM) listed in Table 1. PCR protocol includes 40
159 cycles of: 95°C (5 seconds) and 57°C (30 seconds), carried on CFX96 Real-Time System (Bio-
160 Rad Laboratories, USA). Relative mRNA expression of each gene of interest (GOI, Table I)
161 was quantified using 60S acidic ribosomal protein P0 (PRLP0) as the housekeeping control
162 gene.

163

164 **Table I. List of primers used in this study**

Target gene	Forward primer	Reverse Primer
<i>CFH</i>	5' CTG ATC GCA AGA AAG ACC AGT A 3'	5' TGG TAG CAC TGA ACG GAA TTA G 3'
<i>CFB</i>	5' GCT GTG AGA GAG ATG CTC AAT A 3'	5' GAC TCA CTC CAG TAC AAA G 3'

C3	5' ACG GCC TTT GTT CTC ATC TC 3'	5' CAA GGA AGT CTC CTG CTT TAG T 3'
C5	5' CGA TGG AGC CTG CGT TAA TA 3'	5' CTT GCG ACG ACA CAA CAT TC 3'
CFI	5' - TAC TCA CCT CTC CTG CGA TAA- 3'	5' - GGG CAC TGA TAC GGT AGT TTA C -3'
CCL2	5' GGC TGA GAC TAA CCC AGA AAC 3'	5' GAA TGA AGG TGG CTG CTA TGA 3'
IL6	5' CCA GGA GAA GAT TCC AAA GAT GTA 3'	5' CGT CGA GGA TGT ACC GAA TTT 3'
CXCL8	5' AAA TCT GGC AAC CCT AGT CTG 3'	5' GTG AGG TAA GAT GGT GGC TAA T 3'
RELA	5' CTG TCC TTT CTC ATC CCA TCT T 3'	5' TCC TCT TTC TGC ACC TTG TC 3'
PRLP0	5' GGA GAA ACT GCT GCC TCA TAT C 3'	5' CAG CAG CTG GCA CCT TAT T 3'

165

166 Western Blotting

167 Protein expression was analyzed in both cell lysates and cell supernatants. After debris removal,
 168 cell culture supernatants were precipitated with ice-cold acetone. For protein analysis of cell
 169 lysates, cells were lysed in Pierce IP Lysis Buffer, containing Halt Protease & Phosphatase
 170 Inhibitor (Thermo Fisher, Massachusetts, USA). Protein concentrations were determined with
 171 the Bradford quantification assay, using BSA as a standard. Equal amounts of cell lysates or
 172 equal volumes of cell supernatants were prepared in NuPAGE LDS Sample Buffer, containing
 173 reducing agent (Thermo Fisher, Massachusetts, USA) and analyzed on Novex 8-16% Tris-
 174 Glycine gels (Invitrogen, California, USA). Subsequently proteins were transferred onto PVDF
 175 membranes and western blot detection carried out as previously described (31), using the
 176 primary antibodies listed in Table II. Pictures were acquired with a FusionFX imaging system
 177 (Vilber Lourmat, France) and the intensity density of individual bands was quantified using the
 178 ImageJ software.

179

180 Table II. List of primary antibodies used in this study

Antibody	Supplier	Number	181
β-actin	Cell Signaling	#3700	182
Complement C3	Invitrogen, ThermoFisher	#PA5-21349	183
Factor H (FH)	SantaCruz Biotechnology	sc-166608	184
p-NF-kB p65	Cell Signaling	#3033	185
Total NF-kB p65	Cell Signaling	#8242	186
			187

188

189 C3b ELISA

190 C3/C3b ELISA to evaluate the concentration of C3/C3b in cell culture supernatants was
 191 performed according to the manufacturer's instructions (Abcam, UK). Samples and standard
 192 controls were loaded in 96 well-plates coated with specific C3b antibody. Absorbance was read

193 at a wavelength of 450 nm immediately after the assay procedure using a Spark multimode
194 microplate reader (Tecan, Switzerland). Subtraction readings at 570 nm were taken to correct
195 optical imperfections.

196

197 **Cytokine array**

198 The Proteome Profiler Human Cytokine Array Kit (R&D Systems, Minnesota, USA) was
199 employed to determine the relative levels of 36 different cytokines and the assay was performed
200 according to the manufacturer's instructions. Briefly, the membranes were blocked for 1 h at
201 room temperature. The cellular supernatant samples were further prepared by mixing 400 µl of
202 the sample with 500 µl Array Buffer 4, 600 µl Array Buffer 5 and 15 µl of Detection Antibody
203 Cocktail and incubated for 1 h at room temperature. The prepared mixture was added to the
204 membranes, followed by an incubation period overnight at 4°C. The membranes were washed
205 3 x 10 minutes, incubated in diluted HRP-Streptavidin (1:2000) for 30 minutes, and washed
206 again for 3 x 10 minutes. The Chemi Reagent Mix (1:1 ratio) was dropped onto the membranes,
207 incubated for 1 minute, and the signal was detected by FusionFX (Vilber Lourmat, France) in
208 the automatic mode and, additionally, in an individual programmed mode with an increasing
209 detection time of: 0.5, 1, 1.5, 2, 4, 6, 10 minutes. The results were evaluated with the Fusion
210 software and ImageJ by measuring the intensity density.

211

212 **Bioinformatic analyses**

213 Data analysis of the raw values from the cytokine array as obtained and measured using ImageJ,
214 were normalized to the positive control. For principal component analysis (PCA), values were
215 Pareto scaled by dividing each variable by the square root of the standard deviation to minimize
216 the effect of small noisy variables.

217 The Variable Importance in Projection (VIP) in a Partial Least Square Discriminant
218 Analysis (PLS-DA) was used to identify the most discriminative cytokines for each biological
219 group following siRNA treatment. Similar to the PCA analysis and normalized to the positive
220 control, Pareto scaled values were used. PCA and VIP score analysis were carried out using the
221 R package MetaboAnalystR, integrated in the publicly available platform for statistical analysis
222 metaboanalyst.ca (35).

223

224 **Statistical analysis**

225 The data are presented as mean with the standard error of the mean (SEM) and were generated
226 and tested for their significance with GraphPad Prism 8 software. All data sets were tested for

227 normal distribution, assessed with Shapiro-Wilk normality test. Depending on normal
228 distribution and the parameters to be compared the following tests were performed: Mann-
229 Whitney test was used in case of non-normal distribution, unpaired student's t-test was used to
230 compare siNeg vs either siCFH or siRELA condition and to compare siCFH vs siCFH +
231 siRELA. Ratio paired t-test was used to compare the relative changes between siCFH vs
232 siCFH+siRELA and siCFH vs siCFH treated (FH, C3 or C3b), only when both conditions were
233 normalized to siNeg control. Values were considered significant with $p < 0.05$.
234


235 **Results**

236 ***CFH* loss leads to upregulation of C3 and inflammatory cytokines in RPE cells**

237 In our previous study, we used siRNA silencing of the *CFH* gene to investigate the impact of
238 reduced FH levels and activity in hTERT-RPE1 cells in response to oxidative stress after 48h
239 *in vitro* (31). Here, we used the same model to investigate immune reactivity of RPE cells after
240 *CFH* knockdown and prolonged its silencing period up to 6 days (144h). In this way, we were
241 able to mimic features of an early stage of AMD where the barrier function of RPE cells remains
242 intact, and therefore the protein composition of the retinal microenvironment depends mostly
243 on RPE cells protein production. Using both the short (48h) and the prolonged (144h) silencing
244 period, we investigated the impact of endogenous FH loss on pro-inflammatory cytokine
245 production and on complement system regulation.

246 Efficient *CFH* silencing after 48h was already shown before and reproduced in this
247 study (31). Here, we show that also after 144h *CFH* mRNA was significantly reduced in *CFH*
248 knock-down (siCFH) RPE cells compared to control cells (siNeg). The silencing efficiency of
249 almost 90% after 48h was maintained also at 144h (Fig. 1a). Likewise, FH protein levels
250 remained almost undetectable in cell culture supernatants of siCFH cells after 144h (Fig. 1b).
251 With prolonged FH loss, *C3* gene expression (Fig. 1e) and C3 protein levels (Fig. 1c-d)
252 increased significantly. Levels of *C3* mRNA were found to be 20-fold higher in siCFH cells at
253 both time points (Fig. 1e). Similarly, protein levels of secreted C3 were significantly elevated
254 in siCFH cells, as shown by a 2-fold increase in C3/C3b ELISA (Fig. 1c) and a 4-fold increase
255 in C3/C3b alpha and beta chains in Western Blot (Fig. 1d).

256 Given that early AMD is hallmarked by persistent inflammation (36, 37), we
257 investigated the levels of relevant inflammatory cytokines, including: interleukin-6 (IL6), C-C
258 Motif Chemokine Ligand 2 (CCL2) and interleukin-8 (CXCL8). When FH was downregulated
259 in siCFH cells, we observed an upregulation of IL6 (3-fold at 48h and 2-fold at 144h) and CCL2
260 (2-fold at 48 and 2.5-fold at 144h) (Fig. 1f-g). Moreover, CXCL8 levels were 8-fold upregulated
261 in siCFH cells, significantly after 48h (Fig. 1h). This indicates that reduction of FH levels and
262 activity in RPE cells leads to an upregulation of relevant pro-inflammatory molecules.



263 **Figure 1. Short and sustained FH reduction leads to increased expression levels of C3 and**
 264 **inflammatory cytokines.** hTERT-RPE1 cells were seeded, left to attach overnight and silenced
 265 for 24 hours with negative control (siNeg) or *CFH* specific (siCFH) siRNA. Afterwards, cells
 266 were kept in serum-free medium (SFM) and cell pellets and cell culture supernatants were
 267 collected after 48 and 144 hours. **a** Evaluation of *CFH* expression after 144h by qRT-PCR
 268 analyses. Data are normalized to the housekeeping gene PRLP0 using $\Delta \Delta C_t$ methods. SEM is
 269 shown, n=5. **b** Western blot analyses of FH protein levels in cell culture supernatants of hTERT-
 270 RPE1 cells after 144h. Quantification of signal density of 3 independent experiments is shown.
 271 **c** Western blot analyses of C3/C3b α -chain and β -chain protein levels in cell culture
 272 supernatants of hTERT-RPE1 cells after 144h. Quantification of signal density of 5 independent
 273 experiments is shown. **d** C3/C3b ELISA analyses of cell culture supernatants of hTERT-RPE1
 274 cells after 144h. SEM is shown, n=6. **e-h** Monitoring of gene expression by qRT-PCR analyses
 275 in hTERT-RPE1 cells: **e** complement component 3 (*C3*), **f** interleukin-6 (*IL6*), **g** C-C Motif
 276 Chemokine Ligand 2 (*CCL2*) and **h** interleukin-8 (*CXCL8*). Data are normalized to
 277 housekeeping gene PRPL0 using $\Delta \Delta C_t$ method. SEM is shown, n=5-8. Western Blot images
 278 were cropped, and full-length blots are presented in Supplementary Fig. S1. Significance was
 279 assessed by Student's t-test. *p<0.05, **p<0.01, *** p<0.001, ****p<0.0001.

280 **Cytokine expression mediated by FH loss is driven by NF- κ B activity**


281 Changes in RPE gene expression after FH reduction, suggests that a pro-inflammatory pathway
282 may be regulated by FH in RPE cells. As NF- κ B plays a major role in regulating a variety of
283 cytokine expression levels (38), we next investigated if the activity of NF- κ B was changed by
284 *CFH* silencing. To do so, we monitored the levels of the activated phosphorylated form of the
285 NF- κ B p65 subunit and its total levels in siNeg and siCFH RPE cells over time (Fig. 2a). We
286 found a dramatic and sustained increase in the activation levels of NF- κ B, as shown by the
287 increased relative ratio of phosphorylated/total NF- κ B p65 subunit (Fig. 2b).

288 To investigate a potential direct correlation between reduced FH activity and the
289 observed NF- κ B pathway activation, we employed concomitant double silencing of *CFH* and
290 *RELA*, the gene coding for the NF- κ B p65 subunit. First, *RELA* silencing efficiently reduced
291 the levels of the gene by about 90% in siRELA and siCFH + siRELA cells (Fig. 2c). *CFH*
292 silencing had no impact on the expression level of *RELA* (Fig. 2c). In *RELA* silenced cells, the
293 protein levels of NF- κ B p65 were also greatly reduced (Fig. 2d). Quantification of protein levels
294 for both the phosphorylated form of NF- κ B p65 (Fig. 2e) and total NF- κ B p65 (Fig. 2f) in
295 siRELA and siCFH + siRELA cells show a significant reduction of protein abundance.

296 Next, we evaluated gene expression levels of the identified upregulated cytokines in
297 response to *RELA* silencing. Interestingly, we found that under control conditions (*i.e.* in the
298 presence of FH), the NF- κ B pathway regulates the expression of *CCL2* and *CXCL8*, but not
299 that of *IL6* (Fig. 2g-i). As shown in Fig. 2g, *IL6* levels only rise in the absence of FH activity
300 (siCFH). Conversely, a downregulation of NF- κ B p65 in siCFH cells (siCFH + siRELA),
301 lowers the gene expression of all three cytokines back to basal levels (Fig. 2g-i). In particular,
302 a strong significant reduction was observed for *IL6* (Fig. 2g), *CXCL8* (Fig. 2i) and for *CCL2*
303 (Fig. 2h).

304 Next, we tested whether exogenous application of FH could revert the effects of
305 endogenous siRNA-based *CFH* suppression on both NF- κ B activation as well as the expression
306 of inflammatory cytokines. At the same time, we evaluated the effects of an addition of C3 and
307 C3b. The addition of exogenous complement factors, however, did not change NF- κ B
308 activation levels (Suppl. Fig. S4a-b) nor gene expression levels of *IL6* (Suppl. Fig. S4c) and
309 *CCL2* (Suppl. Fig. S4d) at any of the time points tested (48h and 144h).

310



311 **Figure 2. RPE cells deprived of FH show NF-κB activation and blocking NF-κB abolishes**
 312 **the effects of FH loss on cytokine gene expression levels.** hTERT-RPE1 cells were seeded,
 313 left to attach overnight and silenced for 24 hours with either negative control (siNeg), *CFH*
 314 specific (siCFH) or NFκB/*RELA* specific (siRELA) siRNA or with a combination of siCFH
 315 and siRELA siRNA. Afterwards, cells were kept in serum-free medium (SFM) and cell pellets
 316 and cell culture supernatants were collected after 48 and/or 144 hours. **a** Western blot analyses
 317 of phosphorylated and total levels of p65 NF-κB subunit in cell lysates of hTERT-RPE1 cells
 318 after 48h and 144h. Total actin was used as loading control. **b** Quantification of signal density
 319 of at least 4 independent experiments as reported in a. Bars indicate the signal density ratio
 320 between levels of phosphorylated and total p65 NFκB subunit. **c** Evaluation of *RELA* gene
 321 expression levels by qRT-PCR analyses in hTERT-RPE1 cells after 48h. Data are normalized
 322 to the housekeeping gene *PRPL0* using $\Delta \Delta C_t$ methods. SEM is shown, n=5. **d** Western blot
 323 analyses of phosphorylated and total levels of p65 NFκB subunit in cell lysates of hTERT-
 324 RPE1 cells after 48h. Total actin was used as loading control. **e** Quantification of signal density
 325 of 3 independent experiments in the conditions reported in c-d. Bars indicate the signal density
 326 ratio between phosphorylated p65 NFκB subunit and actin. **f** Quantification of signal density of
 327 3 independent experiments in the conditions reported in c-d. Bars indicate the signal density
 328 ratio between total p65 NFκB subunit and actin. **g-i** Gene expression analyses by qRT-PCR of
 329 hTERT-RPE1 cells in the conditions reported in c-d: **g** interleukin-6 (IL6), **h** C-C Motif
 330 Chemokine Ligand 2 (CCL2) and **i** interleukin-8 (CXCL8). Data are normalized to
 331 housekeeping gene *PRLP0* using $\Delta \Delta C_t$ method. SEM is shown, n=3-5. Western Blot images

332 were cropped, and full-length blots are presented in Supplementary Fig. S2-3. Significance was
333 assessed by Student's t-test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

334


335 In order to assess whether the changes in gene transcription would translate into an
336 inflammatory microenvironment outside of the RPE cells, we monitored the levels of secreted
337 inflammatory factors *via* a cytokine array analyzing the serum free conditioned medium
338 supernatant of hTERT-RPE1 cells after 48 hours (Fig. 3a).

339 Using PCA analysis, we plotted all the signal intensities for each cytokine from all the
340 biological replicates of each group: siNeg, siCFH and siCFH+siRELA. As shown in Fig. 3b,
341 there is clear segregation between siNeg and siCFH as they cluster apart according to the first
342 principal component (PC1), thus indicating a clear effect of siCFH silencing on the RPE
343 cytokine signature. The combination of siCFH + siRELA had little effect on the cytokine profile
344 signature as siCFH + siRELA group cluster tightly with siNeg control (Fig. 3b). This suggests
345 that downregulation of NF- κ B p65 (siRELA) in siCFH silenced RPE cells results in a reversion
346 of the pro-inflammatory phenotype to normal para-inflammatory homeostasis. As the
347 microarray used for analysis only covers a limited number of cytokines and their relative
348 quantification was based on differences in signal detection after blotting, we chose to use a
349 more supervised approach. Variable Importance in Projection (VIP) values from Partial Least
350 Square Discriminant Analysis (PLS-DA) was used to gain a quantitative estimation of the
351 discriminatory power of each individual cytokine (Fig. 3c). VIP score analysis detected 12
352 cytokines that significantly differentiated between the 3 siRNA groups. IL-8 and IL-6, also
353 shown in Fig. 3d and Fig 3e are the 2 cytokines that contribute the most to the segregation
354 between siNeg, siCFH and siCFH + siRELA. Besides these two, most of the cytokines analysed
355 on the array were increased in the siCFH group when compared to the siNeg controls: colony
356 stimulating factor 2 (GM-CSF, Fig. 3f), serpin family E member 1 (Serp in E1, Fig. 3g), C-X-
357 C Motif Chemokine Ligand 1 (CXCL1/GRO α , Fig. 3h), C-C motif chemokine ligand 3 and 4
358 (MIP-1 α /-1 β , Suppl. Fig. S6a), while the effects on MCP-1, IL18 and IL-1a were less
359 pronounced and only slightly changed (Fig. 3i). Most of these cytokines exhibit a decreased
360 level of abundance when silencing of FH (siCFH) and NF- κ B p65 (siRELA) was combined:
361 IL-8 (Fig. 3d), IL-6 (Fig. 3e), GM-CSF (Fig. 3f), Serpin E1 (Fig. 3g), CXCL1/GRO α were
362 reduced to a base level indicating that an inhibition of the NF- κ B pathway can dampen or
363 abrogate the consequences of FH loss (Fig. 3h).

364 An exception to this pattern was seen with interleukin 1 receptor antagonist (IL-1Ra,
365 Fig 3a, c, and Suppl. Fig. S6b), which antagonizes the inflammatory effects of IL-1 α /-1 β *via*
366 competitive binding to their receptors. The upregulation of IL-1Ra as an anti-inflammatory
367 cytokine suggests that its expression is negatively regulated by NF- κ B pathway activity.
368 Minimal differences were observed in between the conditions (Suppl. Fig. S6) for macrophage

369 migration inhibitory factor (MIF), interleukin-1 alpha (IL-1a), and interleukin-18 (IL-18) and
370 interleukin-21 (IL-21), although the latter was slightly reduced in response to siRELA.

371



372 **Figure 3. Blockade of NFκB abolishes the effects of FH loss on secreted cytokines.** hTERT-
 373 RPE1 cells were seeded, left to attach overnight and silenced for 24 hours with either negative
 374 control (siNeg), *CFH* specific (siCFH) or with a combination of siCFH and NFκB/RELA
 375 specific (siRELA) siRNA. Afterwards, cells were kept in serum-free medium (SFM) and cell
 376 culture supernatants were collected after 48h. **a** Representative image of a Proteome Profiler
 377 Human Cytokine Array analysis performed on cell culture supernatants collected from hTERT-
 378 RPE1 cells after 48h. **b** PCA Analysis of the Cytokine array data for all biological replicates,
 379 samples were colored according to the corresponding siRNA treatment group, 95% confidence
 380 regions were plotted and colored according to each group. **c** Variable importance in projection
 381 (VIP) score plot derived from PLS-DA analysis, the top cytokines that contribute to the

382 segregation between the groups were plotted and their differential abundance was color scaled
383 according to their enrichment (red), depletion (blue), or unchanged (grey).
384 **d-i** Quantification of signal density in the conditions reported in a: **d** interleukin-8, IL-8; **e**
385 interleukin-6, IL-6; **f** colony stimulating factor 2, GM-CSF; **g** serpin family E member 1, Serpin
386 E1; **h** C-X-C Motif Chemokine Ligand 1, CXCL1/GRO α ; **i** C-C Motif Chemokine Ligand
387 2, CCL2. SEM is shown. n=3. Significance was assessed by Student's t-test. *p<0.05, **p<0.01,
388 *** p<0.001).
389

390 **FH loss alters transcription of complement genes via the NF- κ B pathway**


391 The transcriptional regulation of complement genes has remained poorly understood in RPE
392 cells, as well as in general. After finding that reduction of FH activity resulted in a marked
393 upregulation of C3 expression (Fig. 1), we investigated whether either suppression of FH
394 expression or NF- κ B activity would regulate the expression levels of additional complement
395 factors or regulators.

396 We observed a significant reduction of *CFH* mRNA levels in siRELA cells (Fig. 4a),
397 followed by reduced levels of FH at the protein level (Fig. 4b). C3 levels were also reduced in
398 siRELA cells, both at the protein level (Fig. 4c) as well as RNA level (Fig. 4d). Addition of
399 exogenous FH could only partially revert the effects of endogenous *CFH* silencing on C3
400 mRNA levels (Suppl. Fig. S8a) and C3 secreted levels (Suppl. Fig. S8b) after 144h of
401 incubation. Supplementation with C3 and C3b had no impact (Suppl. Fig. 8a) at any time point.

402 Subsequently, we investigated the gene expression levels of *CFB*, an important positive
403 regulator of the alternative pathway of the complement system. We found a significant 2.5-fold
404 increase in the *CFB* gene after *CFH* silencing and a return to basal levels after silencing NF- κ B
405 p65, while *CFB* levels were not affected by siRELA alone (Fig. 4e). Addition of exogenous FH
406 could only partially revert the effects of endogenous *CFH* silencing on *CFB* mRNA levels,
407 while addition of C3 and C3b had no effects (Suppl. Fig. S8c). Next, we evaluated the
408 expression of *CFI*, a negative regulator of the complement activation in the presence of FH as
409 a co-factor. The RNA levels of *CFI* were 12-fold higher in siCFH cells and were significantly
410 reduced in siRELA cells. (Fig. 4f). Furthermore, we analysed the expression of *C5*, another
411 major component of the complement cascade. The levels of *C5* RNA (Fig. 4g) were reduced
412 by both silencing FH expression in siCFH cells as well as after NF- κ B p65 silencing in siRELA
413 cells.

414 Most importantly, all factors belonging to the complement system, whose levels were
415 increased in the absence of FH, were reduced *via* suppression of NF- κ B activity. Thus, *CFB*
416 RNA levels were redirected to basal levels (Fig. 4e); as well as a clear reduction of *CFI* RNA
417 levels was observed (Fig. 4f). C3 RNA levels were significantly reduced by half (Fig. 4b) and
418 C3 secreted protein levels were also significantly reduced (Fig. 4c).

419



420 **Figure 4. FH loss alters gene transcription of complement system genes via the NFκB**
 421 **pathway.** hTERT-RPE1 cells were seeded, left to attach overnight and silenced for 24 hours
 422 with either negative control (siNeg), *CFH* specific (si*CFH*), NFκB/RELA specific (siRELA)
 423 siRNA or with a combination of si*CFH* and siRELA siRNA. Afterwards, cells were kept in
 424 serum-free medium (SFM) and cell pellets and cell culture supernatants were collected for after
 425 48h. **a** Evaluation of *CFH* expression by qRT-PCR analyses. Data are normalized to the
 426 housekeeping gene PRPL0 using $\Delta \Delta C_t$ methods. SEM is shown, n=5. **b** Evaluation of *C3*
 427 expression by qRT-PCR analyses. Data are normalized to the housekeeping gene PRPL0 using
 428 $\Delta \Delta C_t$ methods. SEM is shown, n=5. **c** Western blot analyses of C3 α -chain and β -chain protein
 429 levels in cell culture supernatants. Quantification of signal density of 4 independent
 430 experiments is shown. **d** Western blot analyses of FH protein levels in cell culture supernatants.
 431 Quantification of signal density of 3 independent experiments is shown. **e** Evaluation of *CFB*
 432 expression by qRT-PCR analyses. Data are normalized to the housekeeping gene PRPL0 using
 433 $\Delta \Delta C_t$ methods. SEM is shown, n=5. Western Blot images were cropped, and full-length blots
 434 are presented in Supplementary Fig. S7. Significance was assessed by Student's t-test. *p<0.05,
 435 **p<0.01.

436 Discussion

437 Given the strong association of the *CFH* gene with AMD, and a clear role of RPE cells in
438 maintaining homeostasis in the retinal microenvironment, we investigated the role of FH in
439 RPE cells with respect to its impact on balancing molecular mechanisms of inflammation. Here,
440 we demonstrate that endogenously expressed *CFH* in RPE cells modulates inflammatory
441 cytokine production and complement regulation, independent of external complement sources
442 or stressors. We show that decreased *CFH* levels and activity result in increased levels of
443 inflammatory cytokines, chemokines and growth factors, that are known to play a role in AMD,
444 as well as several other neurodegenerative diseases. Although our study reported here does not
445 delineate between the two protein products made by the *CFH* gene (*i.e.* FH and FHL-1) it is
446 reasonable to assume that given FH is the major splice variant expressed by hTERT-RPE1 cells
447 (see Fig. S1) that the biological consequences of *CFH* gene silencing in our study are mediated
448 primarily by FH.

449 Based on the levels of secreted inflammatory proteins and PCA analysis (Fig. 3), we
450 observed a clear segregation between control RPE cells (siNeg) and RPE cells deprived of *CFH*.
451 The main discriminatory factors were IL-6 and IL-8, which were also the most upregulated
452 cytokines after *CFH* silencing. Besides their role in inflammation, IL-6 and IL-8 are both
453 members of the senescence-associated secretory pathway (SASP) and involved in ageing
454 processes. Indeed, H₂O₂-mediated senescence in ARPE19 cells leads to increased levels of IL-
455 6 and IL-8 when FH levels were reduced (39). Moreover, increased systemic IL-6 levels were
456 found in patients with AMD, mostly in relation to the late subtypes of the disease (40).
457 Interestingly, a study exploring potential new drug targets for AMD identified IL-6 as a
458 candidate target (41).

459 We found in RPE cells lacking FH increased secreted levels of GM-CSF (Fig. 3), a
460 growth factor that promotes activation and survival of microglia cells and macrophages (42).
461 Interestingly, GM-CSF levels have been found to be elevated in the vitreous of postmortem
462 human eyes genotyped for the *CFH* Y402H SNP, and in parallel accumulation of choroidal
463 macrophages was observed (43). In this study, local accumulation of GM-CSF was found after
464 stimulation with the anaphylatoxins C3a and C5a (43). Our data suggest that RPE cells may be
465 a source of GM-CSF found in the *CFH* Y402H post-mortem eye.

466 Serpin E1, also known as Plasminogen Activator Inhibitor-1 (PAI-1), was upregulated
467 in siCFH RPE cells. Serpin E1 is involved in ECM remodeling and angiogenesis (44), processes
468 that are altered at the Bruch's membrane/choroid interface in AMD (2). Serpin E1 is also
469 considered a senescence marker in several tissues (44). High levels of Serpin E1 have been

470 associated with neovascularization in AMD and diabetic retinopathy (45). Serpin E1 mediates
471 some of its effects *via* binding to the $\alpha 5\beta 3$ integrin (46), and interestingly also FH and its
472 truncated form FHL-1 modulate RPE function *via* binding a closely related integrin, $\alpha 5\beta 1$ (47).

473 Other factors altered by FH in RPE cells include CXCL1/GRO α , a chemokine
474 responsible for neutrophil recruitment and activation (48) that has been found increased in
475 aqueous humor of AMD patients (49), and MIP-1 α and MIP-1 β , which have been found to be
476 involved in inflammation-mediated damage in the retina (50). FH loss in RPE cells also leads
477 to upregulation of IL-1 α , which has been found to be highly expressed by RPE cells in response
478 to IL-1 β and TNF α stimulation (51). Interestingly, IL-1 β has been found to be highly expressed
479 in iPSC-derived RPE cells carrying the *CFH* 402H variant (52) and TNF α accumulates in the
480 BrM and choroid in eyes from *CFH* 402H donors (53).

481 Our results are in line with independent observations that in AMD, as well as in the
482 presence of the *CFH* 402H variant, inflammation is increased. However, the signaling pathways
483 involved in the regulation of inflammation in RPE cells are not fully characterized, and most
484 importantly the pathway by which FH regulates inflammation in RPE cells was not known. The
485 majority of cytokines differentially regulated in FH-deprived conditions are target of the NF-
486 κ B pathway. NF- κ B plays a central role in regulating cellular responses to inflammation and is
487 often activated in concert with the complement system. NF- κ B consists of transcription factor
488 complexes expressed in most cell types and can be activated in response to a variety of stimuli
489 or stressors, which allow the cell to respond and adapt to variations in the microenvironment
490 including infections, growth factor levels or oxidative stress (32). The most common target
491 genes of the NF- κ B pathway are inflammatory cytokines, responsible for recruitment of
492 neutrophils and macrophages at the inflamed site (38): cells that are also recruited after local
493 complement activation (17). We have shown here, that NF- κ B activation follows suppression
494 of *CFH* expression, which in turn results in an upregulation of NF- κ B dependent cytokines.
495 Reducing NF- κ B levels leads to a reduction in the expression and secretion of most of the
496 upregulated cytokines, including IL-6, IL-8, CCL2, Serpin E1, GM-CSF and CXCL1/GRO α .
497 Consequently, the cytokine profile of the siCFH + siRELA group clusters tightly with the siNeg
498 control.

499 The interaction between the complement system and the NF- κ B pathway has been
500 reported in other cell types and pathologies, mostly in the context of cell response to
501 complement-mediated damage. Here, NF- κ B is suggested to play a pro-survival role. Mouse
502 fibroblasts, HELA cells and HEK293 cells lacking NF- κ B p65, are all more sensitive to
503 complement-mediated damage. Here, the NF- κ B pathway was found to suppress JNK-


504 dependent programmed necrotic cell death, rather than being involved in complement
505 regulation and inflammation, since no changes in the expression or activity of the complement
506 regulators CD46, CD55 and CD59 were observed (54). Also, HUVEC cells and human
507 coronary endothelial cells (ECs) show NF- κ B activation in response to MAC formation, in a
508 AKT/endosomes dependent mechanism (55). Data from *in vitro* and *in vivo* models of
509 Alzheimer disease (AD) support the hypothesis that astroglia, rather than neurons, are the
510 principle site of NF- κ B overactivation and those cells are then primarily responsible for the NF-
511 κ B -dependent increase in C3. Importantly in this study, NF- κ B binding sites were confirmed
512 in the C3 promoter. Moreover, the NF- κ B /C3 axis in astroglia cells was suggested to be
513 dependent on the classical complement, rather than alternative complement pathway, due to
514 changes in gene expression of C1q and C4 and not Cfb and Cfh (56). Interestingly, HIV
515 infection activates NF- κ B in astrocytes and promotes C3 production in a IL6-dependent manner
516 (57). Also, results from kidney *in vivo* models of renal injury, provide evidence that the NF- κ B
517 pathway plays an important role in renal damage mediated by enhanced local complement
518 activation (58).

519 It is important to note that RPE cells, in contrast to all these previously mentioned cell
520 types, show a significant level of tolerance to complement-mediated damage (59). This may
521 explain why they do not exploit the NF- κ B pathway to respond to external complement
522 stimulation, but rather regulate this pathway to maintain physiological levels of complement
523 and inflammatory factors. Here, the NF- κ B pathway was not seen activated as pro-survival
524 pathway to respond to a complement activation mediated insult, since addition of neither C3
525 nor C3b had an impact on NF- κ B activity. However, previous studies have reported that RPE
526 cells show NF- κ B activation in response to oxidative stress. For instance, ARPE19 cells show
527 increased phosphorylation in NF- κ B p65 in response to either short or long exposure to H₂O₂
528 (60). In our previous study we show that FH loss increases oxidative and metabolic stress, both
529 stressors of which may induce NF- κ B activation as a survival mechanism. We have also shown
530 that genes involved in oxidative stress response and mitochondrial stability (*e.g.* PGC1 α) were
531 differentially regulated by complement activation: interestingly these are targets of the NF- κ B
532 pathway as well. Further studies will be necessary to understand the mechanism by which FH
533 loss leads to NF- κ B activation. Being co-expressed in RPE cells, FH could directly modulate
534 NF- κ B pathway activation on the protein level. Alternatively, the absence of FH as an
535 antioxidant factor could activate the NF- κ B pathway in the context of oxidative stress response
536 in RPE cells.

537 The observation, that a subset of cytokines (MIP-1 α , MIP-1 β and IL-1ra), which were
538 increased upon FH loss, were not reduced after silencing of NF- κ B p65 suggests, that additional
539 pathways are likely involved in the interplay between complement and NF- κ B pathway. Several
540 pathways have been described as being involved in the homeostasis of RPE cells, which could
541 be regulated by FH. For example, knock-out of CXCR5 in RPE cells leads to an AMD-like
542 phenotype and transcriptome profile highlights the role of PI3K-Akt and mTOR signaling, as
543 important pathways for RPE homeostasis (61). Another possibility involves the regulation of
544 the transcription factor AP1, which has been found to be regulated together with NF- κ B in
545 response to blue-light mediated damage (62).

546 Although the exact mechanism remains to be discovered, our data contribute to the
547 understanding around how risk alleles in *CFH* which result in reduced FH/FHL-1 activity may
548 increase the risk for AMD. We suggest that in RPE cells, FH and the NF- κ B pathway work in
549 synergy to maintain cellular homeostasis, keeping both pro-inflammatory pathways in balance
550 and check (summarized in Fig. 5). In case either one of them is dysregulated due to genetic risk,
551 age and/or local stressors, the RPE microenvironment changes towards a pro-inflammatory
552 AMD-like phenotype, with NF- κ B as well as the alternative complement pathway acting as
553 major protagonists.

554



555 **Figure 5. Summary schematic of NF-κB-mediated inflammation driven by the loss of**
 556 **CFH.** Reduced levels of *CFH* via RNAi in RPE cells leads to activation of the NF-κB pathway
 557 (blue). The NF-κB pathway regulates gene transcription of inflammatory cytokines (light red)
 558 as well as positive (green) and negative (yellow) regulators of complement activation, secreted
 559 from RPE. FH-deprived RPE cells are characterized by reduced levels of oxidative
 560 phosphorylation (Ox-Phos) and glycolysis, as well as increased oxidative stress and oxidized
 561 lipids levels (ox). Metabolic and oxidative stresses are known positive regulators of the NF-κB
 562 pathway and could contribute to the activation of the NF-κB pathway in FH-reduced conditions
 563 (dotted arrow). Secreted proteins circled in blue are directly modulated through the actions of
 564 the NFκB pathway. Cytokines secreted in FH-deprived RPE cells, which are not regulated by
 565 NF-κB pathway, are labeled grey.
 566

567 References

- 568 1. Zhou, R., and R. R. Caspi. 2010. Ocular immune privilege. *F1000 biology reports* 2.
- 569 2. Curcio, C. A., and M. Johnson. 2013. Chapter 20 - Structure, Function, and Pathology of
570 Bruch's Membrane. In *Retina (Fifth Edition)*. S. J. Ryan, S. R. Sadda, D. R. Hinton, A. P.
571 Schachat, S. R. Sadda, C. P. Wilkinson, P. Wiedemann, and A. P. Schachat, eds. W.B. Saunders,
572 London. 465-481.
- 573 3. Clark, S. J., S. McHarg, V. Tilakaratna, N. Brace, and P. N. Bishop. 2017. Bruch's Membrane
574 Compartmentalizes Complement Regulation in the Eye with Implications for Therapeutic
575 Design in Age-Related Macular Degeneration. *Front Immunol* 8: 1778.
- 576 4. Strauss, O. 2005. The retinal pigment epithelium in visual function. *Physiol Rev* 85: 845-881.
- 577 5. Rashid, K., I. Akhtar-Schaefer, and T. Langmann. 2019. Microglia in Retinal Degeneration.
578 *Front Immunol* 10: 1975.
- 579 6. van Lookeren Campagne, M., J. LeCouter, B. L. Yaspan, and W. Ye. 2014. Mechanisms of age-
580 related macular degeneration and therapeutic opportunities. *The Journal of Pathology* 232:
581 151-164.
- 582 7. Handa, J. T., C. Bowes Rickman, A. D. Dick, M. B. Gorin, J. W. Miller, C. A. Toth, M. Ueffing, M.
583 Zarkin, and L. A. Farrer. 2019. A systems biology approach towards understanding and
584 treating non-neovascular age-related macular degeneration. *Nat Commun* 10: 3347.
- 585 8. Klein, R., T. Peto, A. Bird, and M. R. Vannewkirk. 2004. The epidemiology of age-related
586 macular degeneration. *Am J Ophthalmol* 137: 486-495.
- 587 9. Mullins, R. F., S. R. Russell, D. H. Anderson, and G. S. Hageman. 2000. Drusen associated with
588 aging and age-related macular degeneration contain proteins common to extracellular
589 deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease.
590 *FASEB J* 14: 835-846.
- 591 10. Priya, R. R., E. Y. Chew, and A. Swaroop. 2012. Genetic studies of age-related macular
592 degeneration: lessons, challenges, and opportunities for disease management.
593 *Ophthalmology* 119: 2526-2536.
- 594 11. Ajana, S., A. Cougnard-Gregoire, J. M. Colijn, B. M. J. Merle, T. Verzijden, P. de Jong, A.
595 Hofman, J. R. Vingerling, B. P. Hejblum, J. F. Korobelnik, M. A. Meester-Smoor, M. Ueffing, H.
596 Jacqmin-Gadda, C. C. W. Klaver, C. Delcourt, and E.-R. Consortium. 2020. Predicting
597 Progression to Advanced Age-Related Macular Degeneration from Clinical, Genetic, and
598 Lifestyle Factors Using Machine Learning. *Ophthalmology*.
- 599 12. Heesterbeek, T. J., L. Lorés-Motta, C. B. Hoyng, Y. T. E. Lechanteur, and A. I. den Hollander.
600 2020. Risk factors for progression of age-related macular degeneration. *Ophthalmic Physiol*
601 *Opt* 40: 140-170.
- 602 13. Fritsche, L. G., R. N. Fariss, D. Stambolian, G. R. Abecasis, C. A. Curcio, and A. Swaroop. 2014.
603 Age-related macular degeneration: genetics and biology coming together. *Annu Rev*
604 *Genomics Hum Genet* 15: 151-171.
- 605 14. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for
606 immune surveillance and homeostasis. *Nature immunology* 11: 785-797.
- 607 15. Streilein, J. W. 2003. Ocular immune privilege: the eye takes a dim but practical view of
608 immunity and inflammation. *J Leukoc Biol* 74: 179-185.
- 609 16. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Kohl. 2009. The role of the
610 anaphylatoxins in health and disease. *Mol Immunol* 46: 2753-2766.
- 611 17. Behnke, V., A. Wolf, and T. Langmann. 2020. The role of lymphocytes and phagocytes in age-
612 related macular degeneration (AMD). *Cell Mol Life Sci* 77: 781-788.
- 613 18. Tan, W., J. Zou, S. Yoshida, B. Jiang, and Y. Zhou. 2020. The Role of Inflammation in Age-
614 Related Macular Degeneration. *International journal of biological sciences* 16: 2989-3001.
- 615 19. Heesterbeek, T. J., Y. T. E. Lechanteur, L. Lores-Motta, T. Schick, M. R. Daha, L. Altay, S.
616 Liakopoulos, D. Smailhodzic, A. I. den Hollander, C. B. Hoyng, E. K. de Jong, and B. J.
617 Klevering. 2020. Complement Activation Levels Are Related to Disease Stage in AMD. *Invest*
618 *Ophthalmol Vis Sci* 61: 18.

- 619 20. Keenan, T. D., M. Toso, C. Pappas, L. Nichols, P. N. Bishop, and G. S. Hageman. 2015.
620 Assessment of Proteins Associated With Complement Activation and Inflammation in
621 Maculae of Human Donors Homozygous Risk at Chromosome 1 CFH-to-F13B. *Invest*
622 *Ophthalmol Vis Sci* 56: 4870-4879.
- 623 21. Edwards, A. O., R. Ritter, 3rd, K. J. Abel, A. Manning, C. Panhuysen, and L. A. Farrer. 2005.
624 Complement factor H polymorphism and age-related macular degeneration. *Science* 308:
625 421-424.
- 626 22. Day, A. J., A. C. Willis, J. Ripoché, and R. B. Sim. 1988. Sequence polymorphism of human
627 complement factor H. *Immunogenetics* 27: 211-214.
- 628 23. Clark, S. J., C. Q. Schmidt, A. M. White, S. Hakobyan, B. P. Morgan, and P. N. Bishop. 2014.
629 Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's
630 membrane: implications for age-related macular degeneration. *J Immunol* 193: 4962-4970.
- 631 24. Armento, A., M. Ueffing, and S. J. Clark. 2021. The complement system in age-related
632 macular degeneration. *Cellular and Molecular Life Sciences*.
- 633 25. Skerka, C., N. Lauer, A. A. Weinberger, C. N. Keilhauer, J. Suhnel, R. Smith, U. Schlotzer-
634 Schrehardt, L. Fritsche, S. Heinen, A. Hartmann, B. H. Weber, and P. F. Zipfel. 2007. Defective
635 complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. *Mol*
636 *Immunol* 44: 3398-3406.
- 637 26. Clark, S. J., R. Perveen, S. Hakobyan, B. P. Morgan, R. B. Sim, P. N. Bishop, and A. J. Day. 2010.
638 Impaired binding of the age-related macular degeneration-associated complement factor H
639 402H allotype to Bruch's membrane in human retina. *J Biol Chem* 285: 30192-30202.
- 640 27. Shaw, P. X., L. Zhang, M. Zhang, H. Du, L. Zhao, C. Lee, S. Grob, S. L. Lim, G. Hughes, J. Lee, M.
641 Bedell, M. H. Nelson, F. Lu, M. Krupa, J. Luo, H. Ouyang, Z. Tu, Z. Su, J. Zhu, X. Wei, Z. Feng, Y.
642 Duan, Z. Yang, H. Ferreyra, D. U. Bartsch, I. Kozak, L. Zhang, F. Lin, H. Sun, H. Feng, and K.
643 Zhang. 2012. Complement factor H genotypes impact risk of age-related macular
644 degeneration by interaction with oxidized phospholipids. *Proc Natl Acad Sci U S A* 109:
645 13757-13762.
- 646 28. Molins, B., P. Fuentes-Prior, A. Adan, R. Anton, J. I. Arostegui, J. Yague, and A. D. Dick. 2016.
647 Complement factor H binding of monomeric C-reactive protein downregulates
648 proinflammatory activity and is impaired with at risk polymorphic CFH variants. *Sci Rep* 6:
649 22889.
- 650 29. Swinkels, M., J. H. Zhang, V. Tilakaratna, G. Black, R. Perveen, S. McHarg, A. Inforzato, A. J.
651 Day, and S. J. Clark. 2018. C-reactive protein and pentraxin-3 binding of factor H-like protein
652 1 differs from complement factor H: implications for retinal inflammation. *Sci Rep* 8: 1643.
- 653 30. Mannes, M., A. Dopler, M. Huber-Lang, and C. Q. Schmidt. 2020. Tuning the Functionality by
654 Splicing: Factor H and Its Alternative Splice Variant FHL-1 Share a Gene but Not All Functions.
655 *Frontiers in Immunology* 11.
- 656 31. Armento, A., S. Honisch, V. Panagiotakopoulou, I. Sonntag, A. Jacob, S. Bolz, E. Kilger, M.
657 Deleidi, S. Clark, and M. Ueffing. 2020. Loss of Complement Factor H impairs antioxidant
658 capacity and energy metabolism of human RPE cells. *Sci Rep* 10: 10320.
- 659 32. Oeckinghaus, A., and S. Ghosh. 2009. The NF-kappaB family of transcription factors and its
660 regulation. *Cold Spring Harbor perspectives in biology* 1: a000034.
- 661 33. Singh, S., and T. G. Singh. 2020. Role of Nuclear Factor Kappa B (NF-kappaB) Signalling in
662 Neurodegenerative Diseases: An Mechanistic Approach. *Curr Neuropharmacol* 18: 918-935.
- 663 34. Steinle, J. J. 2020. Role of HMGB1 signaling in the inflammatory process in diabetic
664 retinopathy. *Cellular signalling* 73: 109687.
- 665 35. Pang, Z., J. Chong, S. Li, and J. Xia. 2020. MetaboAnalystR 3.0: Toward an Optimized
666 Workflow for Global Metabolomics. *Metabolites* 10: 186.
- 667 36. Macchioni, L., D. Chiasserini, L. Mezzasoma, M. Davidescu, P. L. Orvietani, K. Fettucciari, L.
668 Salviati, B. Cellini, and I. Bellezza. 2020. Crosstalk between Long-Term Sublethal Oxidative
669 Stress and Detrimental Inflammation as Potential Drivers for Age-Related Retinal
670 Degeneration. *Antioxidants (Basel)* 10.

- 671 37. Kim, S. Y., S. P. Kambhampati, I. A. Bhutto, D. S. McLeod, G. A. Luty, and R. M. Kannan. 2021.
672 Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina
673 in a subretinal lipid induced age-related macular degeneration model. *Exp Eye Res* 203:
674 108391.
- 675 38. Mitchell, S., J. Vargas, and A. Hoffmann. 2016. Signaling via the NF κ B system. *Wiley*
676 *interdisciplinary reviews. Systems biology and medicine* 8: 227-241.
- 677 39. Marazita, M. C., A. Dugour, M. D. Marquioni-Ramella, J. M. Figueroa, and A. M. Suburo. 2016.
678 Oxidative stress-induced premature senescence dysregulates VEGF and CFH expression in
679 retinal pigment epithelial cells: Implications for Age-related Macular Degeneration. *Redox*
680 *Biol* 7: 78-87.
- 681 40. Nahavandipour, A., M. Krogh Nielsen, T. L. Sørensen, and Y. Subhi. 2020. Systemic levels of
682 interleukin-6 in patients with age-related macular degeneration: a systematic review and
683 meta-analysis. *Acta Ophthalmol*.
- 684 41. Wang, S., C. Liu, W. Ouyang, Y. Liu, C. Li, Y. Cheng, Y. Su, C. Liu, L. Yang, Y. Liu, and Z. Wang.
685 2021. Common Genes Involved in Autophagy, Cellular Senescence and the Inflammatory
686 Response in AMD and Drug Discovery Identified via Biomedical Databases. *Transl Vis Sci*
687 *Technol* 10: 14.
- 688 42. Crane, I. J., M. C. Kuppner, S. McKillop-Smith, C. A. Wallace, and J. V. Forrester. 1999.
689 Cytokine regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF)
690 production by human retinal pigment epithelial cells. *Clin Exp Immunol* 115: 288-293.
- 691 43. Wang, J. C. C., S. Cao, A. Wang, E. To, G. Law, J. Gao, D. Zhang, J. Z. Cui, and J. A. Matsubara.
692 2015. CFH Y402H polymorphism is associated with elevated vitreal GM-CSF and choroidal
693 macrophages in the postmortem human eye. In *Molecular vision*. 264-272.
- 694 44. Vaughan, D. E., R. Rai, S. S. Khan, M. Eren, and A. K. Ghosh. 2017. Plasminogen Activator
695 Inhibitor-1 Is a Marker and a Mediator of Senescence. *Arterioscler Thromb Vasc Biol* 37:
696 1446-1452.
- 697 45. Lambert, V., C. Munaut, A. Noël, F. Frankenne, K. Bajou, R. Gerard, P. Carmeliet, M. P.
698 Defresne, J. M. Foidart, and J. M. Rakic. 2001. Influence of plasminogen activator inhibitor
699 type 1 on choroidal neovascularization. *Faseb j* 15: 1021-1027.
- 700 46. Stefansson, S., and D. A. Lawrence. 1996. The serpin PAI-1 inhibits cell migration by blocking
701 integrin α v β 3 binding to vitronectin. *Nature* 383: 441-443.
- 702 47. Choudhury, R., N. Bayatti, R. Scharff, E. Szula, V. Tilakaratna, M. S. Udsen, S. McHarg, J. A.
703 Askari, M. J. Humphries, P. N. Bishop, and S. J. Clark. 2020. FHL-1 interacts with human RPE
704 cells through the α 5 β 1 integrin and confers protection against oxidative stress. *bioRxiv*:
705 2020.2009.2028.317263.
- 706 48. Sawant, K. V., K. M. Poluri, A. K. Dutta, K. M. Sepuru, A. Troshkina, R. P. Garofalo, and K.
707 Rajarathnam. 2016. Chemokine CXCL1 mediated neutrophil recruitment: Role of
708 glycosaminoglycan interactions. *Scientific Reports* 6: 33123.
- 709 49. Agrawal, R., P. K. Balne, X. Wei, V. A. Bijin, B. Lee, A. Ghosh, R. Narayanan, M. Agrawal, and J.
710 Connolly. 2019. Cytokine Profiling in Patients With Exudative Age-Related Macular
711 Degeneration and Polypoidal Choroidal Vasculopathy. *Investigative Ophthalmology & Visual*
712 *Science* 60: 376-382.
- 713 50. Rutar, M., R. Natoli, R. X. Chia, K. Valter, and J. M. Provis. 2015. Chemokine-mediated
714 inflammation in the degenerating retina is coordinated by Müller cells, activated microglia,
715 and retinal pigment epithelium. *Journal of Neuroinflammation* 12: 8.
- 716 51. Sugita, S., Y. Kawazoe, A. Imai, Y. Usui, Y. Iwakura, K. Isoda, M. Ito, and M. Mochizuki. 2013.
717 Mature dendritic cell suppression by IL-1 receptor antagonist on retinal pigment epithelium
718 cells. *Invest Ophthalmol Vis Sci* 54: 3240-3249.
- 719 52. Hallam, D., J. Collin, S. Bojic, V. Chichagova, A. Buskin, Y. Xu, L. Lafage, E. G. Otten, G.
720 Anyfantis, C. Mellough, S. Przyborski, S. Alharthi, V. Korolchuk, A. Lotery, G. Saretzki, M.
721 McKibbin, L. Armstrong, D. Steel, D. Kavanagh, and M. Lako. 2017. An Induced Pluripotent
722 Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays

- 723 Characteristic Features of Age-Related Macular Degeneration and Indicates a Beneficial Role
724 for UV Light Exposure. *Stem Cells* 35: 2305-2320.
- 725 53. Cao, S., J. C. Wang, J. Gao, M. Wong, E. To, V. A. White, J. Z. Cui, and J. A. Matsubara. 2016.
726 CFH Y402H polymorphism and the complement activation product C5a: effects on NF-kappaB
727 activation and inflammasome gene regulation. *Br J Ophthalmol* 100: 713-718.
- 728 54. Gancz, D., M. Lusthaus, and Z. Fishelson. 2012. A Role for the NF-κB Pathway in Cell
729 Protection from Complement-Dependent Cytotoxicity. *The Journal of Immunology* 189: 860-
730 866.
- 731 55. Jane-wit, D., Y. V. Surovtseva, L. Qin, G. Li, R. Liu, P. Clark, T. D. Manes, C. Wang, M.
732 Kashgarian, N. C. Kirkiles-Smith, G. Tellides, and J. S. Pober. 2015. Complement membrane
733 attack complexes activate noncanonical NF-κB by forming an Akt⁺/NIK⁺/signalosome on
734 Rab5⁺ endosomes. *Proceedings of the National Academy of Sciences* 112: 9686-9691.
- 735 56. Lian, H., L. Yang, A. Cole, L. Sun, A. C. Chiang, S. W. Fowler, D. J. Shim, J. Rodriguez-Rivera, G.
736 Tagliabatella, J. L. Jankowsky, H. C. Lu, and H. Zheng. 2015. NFκappaB-activated astroglial
737 release of complement C3 compromises neuronal morphology and function associated with
738 Alzheimer's disease. *Neuron* 85: 101-115.
- 739 57. Nitkiewicz, J., A. Borjabad, S. Morgello, J. Murray, W. Chao, L. Emdad, P. B. Fisher, M. J.
740 Potash, and D. J. Volsky. 2017. HIV induces expression of complement component C3 in
741 astrocytes by NF-κB-dependent activation of interleukin-6 synthesis. *Journal of*
742 *Neuroinflammation* 14: 23.
- 743 58. Liu, M., H. Wang, J. Zhang, X. Yang, B. Li, C. Wu, and Q. Zhu. 2018. NF-κB signaling pathway-
744 enhanced complement activation mediates renal injury in trichloroethylene-sensitized mice.
745 *Journal of Immunotoxicology* 15: 63-72.
- 746 59. Whitmore, S. S., E. H. Sohn, K. R. Chirco, A. V. Drack, E. M. Stone, B. A. Tucker, and R. F.
747 Mullins. 2015. Complement activation and choriocapillaris loss in early AMD: implications for
748 pathophysiology and therapy. *Prog Retin Eye Res* 45: 1-29.
- 749 60. Song, C., S. K. Mitter, X. Qi, E. Beli, H. V. Rao, J. Ding, C. S. Ip, H. Gu, D. Akin, W. A. Dunn, Jr., C.
750 Bowes Rickman, A. S. Lewin, M. B. Grant, and M. E. Boulton. 2017. Oxidative stress-mediated
751 NFκappaB phosphorylation upregulates p62/SQSTM1 and promotes retinal pigmented
752 epithelial cell survival through increased autophagy. *PLoS One* 12: e0171940.
- 753 61. Saddala, M. S., A. Lennikov, A. Mukwaya, and H. Huang. 2020. Transcriptome-Wide Analysis
754 of CXCR5 Deficient Retinal Pigment Epithelial (RPE) Cells Reveals Molecular Signatures of RPE
755 Homeostasis. *Biomedicines* 8.
- 756 62. Kim, J., H. L. Jin, D. S. Jang, K. W. Jeong, and S. Y. Choung. 2018. Quercetin-3-O-α-l-
757 arabinopyranoside protects against retinal cell death via blue light-induced damage in human
758 RPE cells and Balb-c mice. *Food Funct* 9: 2171-2183.
- 759